DK0680513T3 - Målretning af immunogener med lysosomer - Google Patents

Målretning af immunogener med lysosomer

Info

Publication number
DK0680513T3
DK0680513T3 DK94910648T DK94910648T DK0680513T3 DK 0680513 T3 DK0680513 T3 DK 0680513T3 DK 94910648 T DK94910648 T DK 94910648T DK 94910648 T DK94910648 T DK 94910648T DK 0680513 T3 DK0680513 T3 DK 0680513T3
Authority
DK
Denmark
Prior art keywords
endosomal
lysosomal
antigens
compartment
chimeric
Prior art date
Application number
DK94910648T
Other languages
Danish (da)
English (en)
Inventor
J Thomas August
Drew M Pardoll
Frank G Guarnieri
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Application granted granted Critical
Publication of DK0680513T3 publication Critical patent/DK0680513T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
DK94910648T 1993-01-22 1994-01-21 Målretning af immunogener med lysosomer DK0680513T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/006,845 US5633234A (en) 1993-01-22 1993-01-22 Lysosomal targeting of immunogens
PCT/US1994/000588 WO1994017192A2 (en) 1993-01-22 1994-01-21 Lysosomal targeting of immunogens

Publications (1)

Publication Number Publication Date
DK0680513T3 true DK0680513T3 (da) 1999-12-27

Family

ID=21722901

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94910648T DK0680513T3 (da) 1993-01-22 1994-01-21 Målretning af immunogener med lysosomer

Country Status (10)

Country Link
US (1) US5633234A (de)
EP (1) EP0680513B1 (de)
JP (1) JP3581366B2 (de)
AT (1) ATE180835T1 (de)
CA (1) CA2154445C (de)
DE (1) DE69418856T2 (de)
DK (1) DK0680513T3 (de)
ES (1) ES2132395T3 (de)
GR (1) GR3031026T3 (de)
WO (1) WO1994017192A2 (de)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8114414B2 (en) 1994-11-08 2012-02-14 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical cancer
US6051237A (en) † 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
US7635479B2 (en) 2000-03-29 2009-12-22 The Trustees Of The University Of Pennsylvania Composition and methods for enhancing immunogenecity of antigens
US8791237B2 (en) 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
US7794729B2 (en) 1994-11-08 2010-09-14 The Trustees Of The University Of Pennsylvania Methods and compositions for immunotherapy of cancer
US7820180B2 (en) 2004-09-24 2010-10-26 The Trustees Of The University Of Pennsylvania Listeria-based and LLO-based vaccines
US7662396B2 (en) 2001-03-26 2010-02-16 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
US8956621B2 (en) 1994-11-08 2015-02-17 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical dysplasia
DE19534170C1 (de) * 1995-09-14 1997-04-10 Univ Tuebingen Rekombinantes Polypeptid basierend auf der Primärsequenz der invarianten Kette mit mindestens einer Primärsequenz von einem spezifischen T-Zellepitop oder eines Proteinderivats und dieses rekombinante Polypeptid kodierende Nukleinsäuren
US6080409A (en) * 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
IL127912A0 (en) * 1996-07-10 1999-11-30 Immunex Corp Method of activating dendritic cells
US6017527A (en) * 1996-07-10 2000-01-25 Immunex Corporation Activated dendritic cells and methods for their activation
EP0960204A4 (de) * 1996-07-26 2002-01-23 Sloan Kettering Inst Cancer Methoden und reagenzien zur genetischen immunisierung
DE69739385D1 (de) 1996-10-23 2009-06-10 Univ Pennsylvania Verbesserte impfstoffe
US6087174A (en) * 1996-12-26 2000-07-11 Johns Hopkins University, School Of Medicine Growth medium for primary pancreatic tumor cell culture
US7098306B2 (en) * 1997-02-13 2006-08-29 The Regents Of The University Of California Method and compositions for treating hepatocellular cancer
KR100460583B1 (ko) * 1997-02-13 2004-12-08 더 리전츠 오브 더 유니버시티 오브 캘리포니아 간세포 암의 예방 및 치료 방법
US6054133A (en) * 1997-07-10 2000-04-25 The Regents Of The University Of California Anti-microbial targeting for intracellular pathogens
WO1999029883A2 (en) * 1997-12-03 1999-06-17 The Johns Hopkins University Targeting antigen-specific t cells for specific immunotherapy of autoimmune disease
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US7014848B1 (en) 1998-03-20 2006-03-21 Genzyme Corporation Enhanced anti-tumor immunity
CA2322660A1 (en) * 1998-03-20 1999-09-23 Genzyme Corporation Enhanced anti-tumor immunity
ATE518956T1 (de) * 1998-05-13 2011-08-15 Epimmune Inc Expressionsvektoren zur stimulierung einer immunantwort und verfahren zu deren verwendung
ES2371432T3 (es) * 1998-05-13 2012-01-02 Epimmune Inc. Vectores de expresión para estimular una respuesta inmune y procedimientos de uso de los mismos.
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US6667037B1 (en) * 1998-10-09 2003-12-23 Ludwig Institute For Cancer Research Isolated peptides which bind to HLA-B35 molecules, larger peptides which contain these, nucleic acid molecules encoding peptides, and uses thereof
US20040171980A1 (en) * 1998-12-18 2004-09-02 Sontra Medical, Inc. Method and apparatus for enhancement of transdermal transport
CA2368225A1 (en) * 1999-04-08 2000-10-12 The Johns Hopkins University Antigen-specific induction of peripheral immune tolerance
US6849272B1 (en) * 1999-04-21 2005-02-01 Massachusetts Institute Of Technology Endosomolytic agents and cell delivery systems
AU2007201619B2 (en) * 1999-09-16 2011-05-12 Eisai Inc. Nucleic acids encoding polyepitope polypeptides
US20050100928A1 (en) * 1999-09-16 2005-05-12 Zycos Inc., A Delaware Corporation Nucleic acids encoding polyepitope polypeptides
US20030077263A1 (en) * 1999-10-29 2003-04-24 Immunex Corporation Method of activating dendritic cells
US7462354B2 (en) * 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
US20040248113A1 (en) * 1999-12-28 2004-12-09 Alessandro Sette Method and system for optimizing multi-epitope nucleic acid constructs and peptides encoded thereby
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
WO2002000174A2 (en) 2000-06-28 2002-01-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US8771702B2 (en) 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
US7700344B2 (en) 2001-03-26 2010-04-20 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
AU2002307145B2 (en) 2001-04-05 2007-11-29 The John Hopkins University Chimeric vaccines
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20040005309A1 (en) * 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
US7560424B2 (en) * 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
EP1436316B1 (de) * 2001-04-30 2008-01-23 ZyStor Therapeutics , Inc. Subzelluläres targeting von therapeutischen proteinen
CA2446788A1 (en) 2001-05-09 2002-11-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20030072761A1 (en) * 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
EP1581119B1 (de) 2001-12-17 2013-01-30 Corixa Corporation Zusammensetzungen und verfahren zur behandlung und diagnose von entzündlicher darmerkrankung
ATE350480T1 (de) * 2002-10-11 2007-01-15 Imvision Gmbh Moduläre antigen-transporter moleküle (mat- moleküle) zur modulierung von immunreaktionen, zugehörige konstrukte, verfahren und verwendungen
WO2004037175A2 (en) * 2002-10-21 2004-05-06 Mgi Pharma Biologics, Inc. Compositions and methods for treating human papillomavirus-mediated disease
WO2004048537A2 (en) * 2002-11-25 2004-06-10 Exelixis, Inc. Lamps as modifiers of the p53 pathway and methods of use
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
DK1589934T3 (en) 2003-01-06 2015-12-21 Corixa Corp Certain AMINOAL COOLER GLUCOSAMINIDE PHOSPHATE COMPOUNDS AND APPLICATION
EP1608675B1 (de) * 2003-03-28 2011-08-17 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Immunogenetische hiv-1 multi-klade, multivalente konstrukte und deren verwendung
ATE465250T1 (de) * 2004-02-10 2010-05-15 Zystor Therapeutics Inc Saure alpha-glukosidase und fragmente davon
JP4691495B2 (ja) * 2004-07-15 2011-06-01 一般財団法人化学及血清療法研究所 コロナウイルススパイクｓ１融合蛋白及びその発現ベクター
CA2504451A1 (en) * 2004-08-10 2006-02-10 Geron Corporation Dendritic cell vaccines for treating cancer made from embryonic stem cells
US7935804B2 (en) 2006-03-01 2011-05-03 Aduro Biotech Engineered Listeria and methods of use thereof
US20070269457A1 (en) * 2006-05-16 2007-11-22 The Buck Institute For Age Research Immunotherapeutic compositions and methods
EP2476437B1 (de) * 2006-08-11 2018-11-28 Life Sciences Research Partners VZW Immunogene Peptide und deren Verwendung bei Immunerkrankungen
US8268326B2 (en) 2006-08-15 2012-09-18 The Trustees Of The University Of Pennsylvania Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof
ES2657168T3 (es) 2006-08-15 2018-03-01 The Trustees Of The University Of Pennsylvania Composiciones que comprenden HMW-MAA y fragmentos de este para el tratamiento del cáncer
CA2669347A1 (en) * 2006-11-13 2008-05-29 Zystor Therapeutics, Inc. Methods for treating pompe disease
SI2152358T1 (sl) 2007-04-27 2011-08-31 Echo Therapeutics Inc Naprava za prodiranje skozi koĺ˝o za analizno merjenje ali za transdermalni prenos zdravil
US7794718B2 (en) 2007-11-01 2010-09-14 Perseid Therapeutics, LLC Immunosuppressive polypeptides and nucleic acids
US20120009678A1 (en) * 2008-02-14 2012-01-12 Jean-Marie Saint-Remy Immunotherapy targeting intracellular pathogens
EP2623115A1 (de) 2008-02-14 2013-08-07 Life Sciences Research Partners VZW Immunogene Beeinflussung von Tumoren und Tumorzellen
EP2623124A1 (de) 2008-02-14 2013-08-07 Life Sciences Research Partners VZW Beseitigung von Immunantworten an virale Vektoren
CA2715536C (en) 2008-02-14 2018-01-16 Life Sciences Research Partners Vzw Cd4+ t-cells with cytolytic properties
BRPI0912225A2 (pt) * 2008-05-07 2018-03-20 Zystor Therapeutics, Inc. peptídeos de direcionamento lisossomais e usos dos mesmos
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
ES2741730T3 (es) 2008-05-19 2020-02-12 Advaxis Inc Sistema de administración doble para antígenos heterólogos que comprende una cepa de Listeria recombinante atenuada por la mutación de dal/dat y la deleción de ActA que comprende una molécula de ácido nucleico que codifica una proteína de fusión de listeriolisina O - antígeno prostático específico
JP5539411B2 (ja) 2009-03-04 2014-07-02 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 血管新生因子を含む組成物およびその使用方法
ES2618881T3 (es) 2009-04-22 2017-06-22 Indiana University Research And Technology Corporation Colágeno V para su uso en el tratamiento del asma
US8785168B2 (en) 2009-06-17 2014-07-22 Biomarin Pharmaceutical Inc. Formulations for lysosomal enzymes
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
WO2011106705A2 (en) 2010-02-26 2011-09-01 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Dna-protein vaccination protocols
ES2625406T3 (es) 2010-03-25 2017-07-19 Oregon Health & Science University Glicoproteínas de CMV y vectores recombinantes
US9226958B2 (en) 2010-10-01 2016-01-05 University Of Georgia Research Foundation, Inc. Use of Listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
ES2924027T3 (es) 2010-11-25 2022-10-04 Imcyse Sa Péptidos inmunogénicos para su uso en la prevención y/o tratamiento de enfermedades infecciosas, enfermedades autoinmunitarias, respuestas inmunitarias a alofactores, enfermedades alérgicas, tumores, rechazo de injerto y respuestas inmunitarias contra vectores virales usados para terapia génica o vacunación génica
WO2012125551A1 (en) 2011-03-11 2012-09-20 Advaxis Listeria-based adjuvants
PL2691530T3 (pl) 2011-06-10 2019-02-28 Oregon Health & Science University Glikoproteiny i rekombinowane wektory CMV
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP2586461A1 (de) 2011-10-27 2013-05-01 Christopher L. Parks Von einem eingehüllten Virus abgeleitete Virenpartikel
GB201201511D0 (en) 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
SG11201405605VA (en) 2012-03-12 2014-10-30 Advaxis Inc SUPPRESSOR CELL FUNCTION INHIBITION FOLLOWING <i>LISTERIA</i> VACCINE TREATMENT
EP2861240B1 (de) 2012-06-15 2020-09-09 Immunomic Therapeutics, Inc. Nukleinsäuren zur behandlung von allergien
EP2679596B1 (de) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 Env-proteinvariante
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
EP2848937A1 (de) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Verfahren zur Identifizierung neuartiger HIV-1-Immunogene
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
CA2943690A1 (en) 2014-03-31 2015-10-08 Boehringer Ingelheim Vetmedica Gmbh Improved modular antigen transportation molecules and uses therof
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
EP3069730A3 (de) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US20180346520A1 (en) 2015-05-13 2018-12-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Methods and compositions for inducing an immune response using conserved element constructs
US10729791B2 (en) 2015-05-18 2020-08-04 Imcyse Sa Animal models for evaluating pharmaceutical compounds
EP3297680A2 (de) 2015-05-20 2018-03-28 Yeda Research and Development Co. Ltd Verfahren zum targeting von seneszenten zellen
CA2995771A1 (en) 2015-09-25 2017-03-30 Imcyse Sa Improved methods and compounds for eliminating immune responses to therapeutic agents
JP2018527395A (ja) 2015-09-30 2018-09-20 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハーＢｏｅｈｒｉｎｇｅｒ Ｉｎｇｅｌｈｅｉｍ Ｖｅｔｍｅｄｉｃａ ＧｍｂＨ 改良モジュール型抗原移送分子及び動物におけるその使用
IL262286B2 (en) 2016-04-19 2023-12-01 Imcyse Sa Novel immunogenic peptides that bind CD1D
US11826423B2 (en) 2016-11-16 2023-11-28 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
BR112019022108A2 (pt) 2017-04-22 2020-05-12 Immunomic Therapeutics, Inc. Construções de lamp aprimoradas
KR20240027895A (ko) 2017-05-02 2024-03-04 이뮤노믹 쎄라퓨틱스, 인크. 암 항원을 포함하는 lamp (리소솜 연관 막 단백질) 구축물
EP3648791A1 (de) * 2017-07-04 2020-05-13 CureVac AG Neuartige nukleinsäuremoleküle
US20210163957A1 (en) 2018-05-11 2021-06-03 Astellas Pharma Inc. Nucleic acid for treating mite allergy
US20210163549A1 (en) 2018-05-11 2021-06-03 Astellas Pharma Inc. Nucleic acid for treating crustacean allergy
US20210261647A1 (en) 2018-05-15 2021-08-26 Immunomic Therapeutics, Inc Lamp constructs comprising allergens
GB2605276B (en) 2019-09-03 2024-08-07 Myeloid Therapeutics Inc Methods and compositions for genomic integration
CA3153850A1 (en) 2019-10-18 2021-04-22 Teri Heiland Improved lamp constructs comprising cancer antigens
EP4072574A4 (de) * 2019-12-11 2024-09-11 Myeloid Therapeutics Inc Therapeutische zellzusammensetzungen und verfahren zur herstellung und verwendungen davon
JP2023549140A (ja) 2020-11-04 2023-11-22 マイエロイド・セラピューティクス，インコーポレーテッド 操作されたキメラ融合タンパク質組成物およびその使用方法
MX2023010916A (es) 2021-03-17 2023-12-14 Myeloid Therapeutics Inc Composiciones de proteinas de fusion quimericas modificadas por ingenieria y metodos de uso de las mismas.
CN119233982A (zh) 2022-04-10 2024-12-31 免疫治疗有限公司 包含免疫应答增强基因的双顺反子lamp构建体及其使用方法
WO2024246427A1 (en) 2023-05-29 2024-12-05 Onni Biotechnologies Oy Fas ligand variant and recombinant cell having increased cytotoxicity and greater survival

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237115A (en) * 1977-11-23 1980-12-02 Bactex, Inc. Method of immunization against enterotoxogenic infection by Escherichia coli
US4397844A (en) * 1978-02-24 1983-08-09 Ciba-Geigy Corporation Antigen derivatives and processes for their preparation
GB2026340B (en) * 1978-07-03 1982-12-22 Ash P Stabilising microvesicles
US4406885A (en) * 1978-12-28 1983-09-27 Research Corporation Preparation of native oncornavirus envelope subunits and vaccines therefrom
US4400376A (en) * 1979-03-27 1983-08-23 National Research Development Corporation Immunological preparations
US4681762A (en) * 1979-05-23 1987-07-21 Research Corporation Genetically attenuated bacterial vaccines with multiple mutations of the same phenotype
US4769330A (en) * 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4593002A (en) * 1982-01-11 1986-06-03 Salk Institute Biotechnology/Industrial Associates, Inc. Viruses with recombinant surface proteins
US4578458A (en) * 1983-03-23 1986-03-25 Brigham And Women's Hospital Mucoid exopolysaccharide vaccine against Pseudomonas aeruginosa
US4738846A (en) * 1984-08-30 1988-04-19 The Salk Institute For Biological Studies Vaccine for vesicular stomatitis virus
ZA858044B (en) * 1984-11-01 1987-05-27 American Home Prod Oral vaccines
US5260422A (en) * 1988-06-23 1993-11-09 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
AU2752892A (en) * 1991-09-26 1993-04-27 Oklahoma Medical Research Foundation Fusion proteins targeted to lysosomes, for the treatment of aids

Also Published As

Publication number Publication date
JPH08505878A (ja) 1996-06-25
DE69418856D1 (de) 1999-07-08
US5633234A (en) 1997-05-27
ATE180835T1 (de) 1999-06-15
WO1994017192A3 (en) 1994-09-15
EP0680513B1 (de) 1999-06-02
JP3581366B2 (ja) 2004-10-27
CA2154445A1 (en) 1994-08-04
DE69418856T2 (de) 2000-01-20
EP0680513A1 (de) 1995-11-08
WO1994017192A2 (en) 1994-08-04
CA2154445C (en) 2007-06-26
ES2132395T3 (es) 1999-08-16
GR3031026T3 (en) 1999-12-31

Similar Documents

Publication Publication Date Title
DK0680513T3 (da) Målretning af immunogener med lysosomer
Zeng et al. Self-adjuvanting nanoemulsion targeting dendritic cell receptor Clec9A enables antigen-specific immunotherapy
WO2002080851A3 (en) Chimeric vaccines
Barbuto et al. Induction of innate and adaptive immunity by delivery of poly dA: dT to dendritic cells
EP1363660A4 (de) &#34;überlegene molekulare vakzine auf basis selbstreplizierender rna, suizid-dna oder nacktem dna-vektor, zur verknüpfung von antigen mit polypeptid zur förderung der antigenpräsentation&#34;
PL338478A1 (en) Immunological response in respect to hpv antigens induced by compositions comprising a hpv antigen and a shock protein or expression vector capable to express such protein
RU2017138373A (ru) Праймирование иммунного ответа
LV12085A (lv) Dendritiskas sunas stimulejosais faktors
Colluru et al. B lymphocytes as direct antigen-presenting cells for anti-tumor DNA vaccines
MX2023010640A (es) Péptidos neoantigénicos transmembranales.
Thalmensi et al. A DNA telomerase vaccine for canine cancer immunotherapy
Crowley et al. Neoleukin-2 enhances anti-tumour immunity downstream of peptide vaccination targeted by an anti-MHC class II VHH
WO2006065821A8 (en) Improved dna immunization with recombinase/transposase
Yi et al. Improved efficacy of DNA vaccination against breast cancer by boosting with the repeat beta-hCG C-terminal peptide carried by mycobacterial heat-shock protein HSP65
Chowdhury et al. Generation of high titer antisera in rabbits by DNA immunization
Bråve et al. Late administration of plasmid DNA by intradermal electroporation efficiently boosts DNA-primed T and B cell responses to carcinoembryonic antigen
CN102657854A (zh) 多表位疫苗yl66以及在制备肿瘤治疗性疫苗中的应用
Tan et al. Intramuscular immunization with DNA construct containing Der p 2 and signal peptide sequences primed strong IgE production
ATE395422T1 (de) Chimäre antikörper zur abgabe von antigenen an selektierte zellen des immunsystems
He et al. Antigen epitope-expressing cytokines for DNA immunization
Neal et al. Hydrodynamic limb vein delivery of a xenogeneic DNA cancer vaccine effectively induces antitumor immunity
Cafri et al. Development of novel genetic cancer vaccines based on membrane‐attached β2 microglobulin
Johansson et al. Intracellular targeting of CEA results in Th1‐type antibody responses following intradermal genetic vaccination by a needle‐free jet injection device
Hadi et al. Development of Delivery Systems Enhances the Potency of Cell‐Based HIV‐1 Therapeutic Vaccine Candidates
Noyan et al. Naive Tumour‐Specific CD4+ T Cells were Efficiently Primed in Acute Lymphoblastic Leukaemia